A5089685782- Asthma and respiratory diseases
- Sinusitis and nasal conditions
- Allergic Rhinitis and Sensitization
- IL-33, ST2, and ILC Pathways
- Respiratory and Cough-Related Research
- Eosinophilic Esophagitis
- Dermatology and Skin Diseases
- Nasal Surgery and Airway Studies
- Otitis Media and Relapsing Polychondritis
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pediatric health and respiratory diseases
- Olfactory and Sensory Function Studies
- Head and Neck Surgical Oncology
- Cardiac electrophysiology and arrhythmias
- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Mycobacterium research and diagnosis
- Cerebrospinal fluid and hydrocephalus
- Coronary Interventions and Diagnostics
- Inhalation and Respiratory Drug Delivery
- Pneumocystis jirovecii pneumonia detection and treatment
- Antifungal resistance and susceptibility
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Sanofi (United States)
2024-2025
Kingston Health Sciences Centre
2025
University of Lausanne
2025
Sanofi (France)
2015-2024
Anhui Normal University
2024
Sherwood Forest Hospitals NHS Foundation Trust
2021-2024
Kings Mill Hospital
2021-2024
University of North Carolina Hospitals
2024
Deen Dayal Upadhyaya Gorakhpur University
2024
Harvard University
2024
Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy safety in patients with uncontrolled asthma.
Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral glucocorticoid use patients with severe asthma while maintaining control unknown.We randomly assigned 210 glucocorticoid-treated to receive add-on dupilumab (at dose of 300 mg) or placebo every 2 weeks for 24 weeks. After dose-adjustment period before randomization, doses were adjusted downward trend from week 4 20 then...
BackgroundDupilumab blocks the shared receptor component for IL-4 and IL-13, key drivers of type 2 inflammation, including IgE-mediated allergic inflammation in asthma. In LIBERTY ASTHMA QUEST (NCT02414854) study, dupilumab reduced severe asthma exacerbations improved forced expiratory volume 1 second (FEV1) patients with uncontrolled, moderate-to-severe greater efficacy observed elevated inflammatory biomarkers (blood eosinophils fractional exhaled nitric oxide) at baseline.ObjectiveWe...
Chronic rhinosinusitis (CRS) is a common yet under-recognised chronic inflammatory disease of the nose and paranasal sinuses that classified according to presence (CRSwNP) or absence (CRSsNP) nasal polyps.This paper reports methodology descriptive results Global Allergy Asthma European Network (GALEN) cohort. We established large CRS cohort within GALEN consortium (European FP6 research initiative) identify endotypes, natural course, its impact on health-related quality life (HRQoL)....
Objectives/Hypothesis Establish treatment patterns and economic burden in US patients with chronic rhinosinusitis nasal polyposis (CRSwNP) versus without (CRS). Determine comparative costs of subgroups high clinical burden. Study Design Observational, retrospective, case‐control study. Methods This study matched CRSwNP to CRS (1:1) using the Truven Health MarketScan claims database. Categorical continuous variables were compared McNemar test paired t (normal distribution) or Wilcoxon signed...
The GALEN rhinosinusitis cohort: chronic with nasal
Abstract Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) negatively affects health‐related quality of life (HRQoL). In a previously reported randomized clinical trial (NCT01920893), addition dupilumab to mometasone furoate in patients CRSwNP refractory intranasal corticosteroids (INCS) significantly improved endoscopic, radiographic, and endpoints patient‐reported outcomes. The objective this analysis was examine the impact treatment on HRQoL productivity using secondary...
Chronic rhinosinusitis with nasal polyps (CRSwNP) and type 2 asthma share the same inflammatory pathophysiology are frequent comorbidities. Dupilumab, a fully human monoclonal antibody, blocks shared receptor component for interleukin 4 13, which key central drivers of inflammation.We report effect dupilumab vs placebo on outcome measures upper lower airways health-related quality life (HRQoL) in pooled population patients CRSwNP comorbid from phase 3 SINUS-24 (NCT02912468) SINUS-52...
BackgroundLoss of smell (LoS) is one the most troublesome and difficult-to-treat symptoms severe chronic rhinosinusitis with nasal polyps (CRSwNP).ObjectiveTo assess impact dupilumab on sense in CRSwNP.MethodsIn randomized SINUS-24 SINUS-52 studies, adults CRSwNP received 300 mg subcutaneously or matching placebo every 2 weeks for 24 52 weeks, respectively. Smell was assessed using daily patient-reported LoS score (0–3) University Pennsylvania Identification Test (UPSIT; 0–40). Data from...
Children with moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of-care therapy. The monoclonal antibody dupilumab has been approved for treatment adults and adolescents as well other type 2 inflammatory diseases.
Objectives/Hypothesis The 22‐item Sinonasal Outcome Test (SNOT‐22) is a validated chronic rhinosinusitis health‐related quality‐of‐life outcome (HRQoL) measure; however, SNOT‐22 domains have not been specifically for with nasal polyps (CRSwNP). Study Design Validation of domain structure, using data from 3 randomized, placebo‐controlled, double‐blinded, multicenter clinical trials dupilumab in adults moderate‐to‐severe CRSwNP. Methods Preliminary dimensional structure was derived by...
Abstract Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2‐mediated inflammatory disease high symptom burden and reduced health‐related quality of life (HRQoL). This report aimed to comprehensively understand the effects dupilumab on domains HRQoL, their individual elements, health status in patients severe CRSwNP from phase 3 SINUS‐24 (NCT02912468) SINUS‐52 (NCT02898454) trials. Methods Patients were randomized ( n = 438) or placebo 286) for 24 weeks...
Abstract This observational study assessed the prevalence of co-existing type 2 inflammatory conditions [T2Cs; asthma, atopic dermatitis (AD), allergic rhinitis, and chronic rhinosinusitis with nasal polyps (CRSwNP)] in patients moderate-to-severe (M/S) M/S CRSwNP, or AD, real-world setting. Data from 761 physicians US EUR5 were sourced Adelphi Disease-Specific Programmes covering asthma ( n = 899), CRSwNP 683), AD 1497). At least one T2C was identified 66%, 69%, 46% cohorts, respectively,...
Purpose This study explores the influence of core self-evaluation (CSE) on students’ academic self-efficacy, anxiety and interpersonal responses. It investigates how internal beliefs impact success among Chinese higher education students. Design/methodology/approach A qualitative research design was employed, using semi-structured interviews with 30 students from various disciplines at H University. The thematic analysis utilized to interpret data. Findings findings suggest that levels CSE...
Limited data exist on cryoablation of atrial fibrillation (Cryo-AF) using the newly available third-generation (Arctic Front Advance-Short Tip [AFA-ST]) cryoballoon.In this multicenter study, we evaluated safety and efficacy Cryo-AF AFA-ST vs second-generation Advance [AFA]) cryoballoon.We examined procedural short- long-term clinical outcomes associated with a first-time performed in 355 consecutive patients (254/355 [72%] paroxysmal AF), either (n = 102) or AFA 253) cryoballoon...
BackgroundComorbid perennial allergic rhinitis (PAR) or year-round aeroallergen sensitivity substantially contributes to disease burden in patients with asthma. Dupilumab blocks the shared receptor for interleukin (IL) 4 and IL-13, key drivers of type 2 inflammation that play important roles asthma PAR. In LIBERTY ASTHMA QUEST trial (NCT02414854), dupilumab reduced severe exacerbations improved forced expiratory volume 1 second (FEV1) uncontrolled, moderate-to-severe asthma, greater efficacy...
BackgroundDupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13 signaling, key drivers of type 2 inflammation. In phase 3 study (NCT02414854), add-on dupilumab 200 mg/300 mg every weeks, versus placebo, significantly reduced severe asthma exacerbations improved pre-bronchodilator forced expiratory volume in 1 second (FEV1) quality-of-life measures patients with uncontrolled, moderate-to-severe asthma, greater efficacy observed those high...
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilumab, fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 interleukin-13, key drivers 2-mediated inflammation. We report results pooled analyses from randomised, double-blind, placebo-controlled phase 3 studies (SINUS 24...
Type 2 inflammatory diseases often coexist in patients. Dupilumab targets type inflammation and has demonstrated treatment benefits patients with atopic dermatitis (AD), asthma, chronic rhinosinusitis nasal polyps (CRSwNP) an acceptable safety profile.This post hoc analysis across five phase 3 studies moderate to severe AD or CRSwNP, evaluated time of onset duration the response.Patients received subcutaneous dupilumab 200/300 mg placebo. Assessments included Eczema Area Severity Index, Peak...
Dupilumab has shown long-term treatment benefits in children with uncontrolled asthma. We assessed more detail the impact of dupilumab on asthma control and health-related quality life (HRQoL) their caregivers.Children aged 6-11 years moderate-to-severe type 2 (baseline blood eosinophils ≥150 cells·µL-1 or fractional exhaled nitric oxide ≥20 ppb; n=350) were treated placebo for 52 weeks VOYAGE study. Primary outcomes these analyses (change from baseline Asthma Control Questionnaire 7...